TRIB2 and small cell lung carcinoma: In view of the challenge in obtaining SCLC tumor tissue before therapy and upon progression to compare their expression of TRIB2, we have started to develop similar SCLC in vivo models of Cisplatin-resistance using patient-derived SCLC tumor samples.